Shen Cheng

Dr. Shen Cheng

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SCShen Cheng
Shen Cheng
SNSusheel Kumar Nethi
Susheel Kumar Nethi
MAMahmoud Al-Kofahi
Mahmoud Al-Kofahi
SPSwayam Prabha
Swayam Prabha
Nano-engineered mesenchymal stem cells (nano-MSCs) are promising targeted drug delivery platforms for treating solid tumors. MSCs engineered with paclitaxel (PTX) loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) are efficacious in treating lung and ovarian tumors in mouse models. The quantitative description of pharmacokinetics (PK) and pharmacodynamics (PD) of nano-MSCs is crucial for optimizing their therapeutic efficacy and clinical translatability. However, successful translation of nano-MSCs is challenging due to their complex composition and physiological mechanisms regulating their pharmacokinetic-pharmacodynamic relationship (PK–PD). Therefore, in this study, a mechanism-based preclinical PK–PD model was developed to characterize the PK–PD relationship of nano-MSCs in orthotopic A549 human lung tumors in SCID Beige mice. The developed model leveraged literature information on diffusivity and permeability of PTX and PLGA NPs, PTX release from PLGA NPs, exocytosis of NPs from MSCs as well as PK and PD profiles of nano-MSCs from previous in vitro and in vivo studies. The developed PK–PD model closely captured the reported tumor growth in animals receiving no treatment, PTX solution, PTX-PLGA NPs and nano-MSCs. Model simulations suggest that increasing the dosage of nano-MSCs and/or reducing the rate of PTX-PLGA NPs exocytosis from MSCs could result in improved anti-tumor efficacy in preclinical settings.

14 June 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ASAbdelrahman Saqr
Abdelrahman Saqr
SCShen Cheng
Shen Cheng
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
Christopher StaleyChristopher Staley
Christopher Staley
PJPamala A. Jacobson
Pamala A. Jacobson
Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF). MPA undergoes glucuronidation to form MPA glucuronide (MPAG) which is deglucuronidated by bacterial β‐glucuronidases and reformed as MPA through enterohepatic circulation (EHC). We studied the stool microbiome effect on the pharmacokinetics of MPA, its metabolites, and EHC in hematopoietic cell transplant (HCT) recipients using a semi‐mechanistic population pharmacokinetic model. Microbiome communities were identified using correlation network analysis, and their impact on pharmacokinetics was assessed using full fixed‐effects modeling. Simulations were then conducted to evaluate MMF dosing regimens and to assess the impact of community abundance on EHC and MPA therapeutic target achievement. High abundance of Bacteroides uniformis ‐dominant and Bacteroides vulgatus ‐dominant communities was associated with higher EHC and an increase in MPA exposure. Low abundance of these communities was associated with a 52–80% and 4–83% lower EHC and MPA exposure, respectively. Simulations showed 70% of individuals with low abundance of these communities achieved the therapeutic target at the typical HCT MMF dose of 1,000 mg Q8 hours IV; however, ≥ 95% were within the therapeutic target at 1,250 mg Q8 hours or 1,750 mg Q12 hours. EHC accounted for 34% of the MPA area under the curve. Elimination of EHC reduced troughs by 100%. This work quantifies the microbiome’s effect on pharmacokinetics, paving the way for future microbiome‐informed dosing to optimize therapeutic target attainment.

5 March 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
RGRamon Garcia
Ramon Garcia
SCShen Cheng
Shen Cheng
FGFiona Glassman
Fiona Glassman
ASAnkur Sharma
Ankur Sharma
BMBernardo De Miguel‐Lillo
Bernardo De Miguel‐Lillo
PNPartha Nandy
Partha Nandy
Hereditary angioedema (HAE) is a rare genetic disease that manifests as recurrent, unpredictable, and potentially life‐threatening attacks of angioedema. Garadacimab is a first‐in‐class, fully human, monoclonal antibody targeting activated factor XII (FXIIa) that is under clinical development for the long‐term prophylaxis of HAE attacks. We developed population pharmacokinetic (PK)/pharmacodynamic (PD)/exposure–response (ER) models using pooled data across clinical studies to quantify the relationship between garadacimab concentration and the relative risk of HAE attacks and to support the rationale for 200 mg once‐monthly dosing. The PK of garadacimab was adequately characterized by a two‐compartment model with first‐order absorption and elimination. The PD, as analyzed by FXIIa‐mediated kallikrein activity, was adequately characterized by a direct inhibitory response model. PK/PD parameters were generally consistent across multiple covariates. ER analysis based on a repeated‐time‐to‐event model showed that administration of garadacimab 200 mg subcutaneously (SC) once monthly results in 75% of patients reaching the target therapeutic threshold (90% reduction in relative risk of attack vs. run‐in). Use of a loading dose (two 200 mg SC injections) as the first administration achieved steady‐state PK exposures and PD response, with 85% of patients having exposures surpassing the therapeutic threshold. The models support the use of garadacimab 200 mg SC once‐monthly dosing in patients aged ≥ 12 years, with no need for dose adjustments, and indicate that, due to the achievement of garadacimab steady‐state exposures after the first administration, the use of a loading dose may facilitate the early onset of protection against HAE attacks, as observed in clinical studies.

30 September 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
SSSiddhee Anand Sahasrabudhe
Siddhee Anand Sahasrabudhe
SCShen Cheng
Shen Cheng
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
JJJeanine R. Jarnes
Jeanine R. Jarnes
NWNeal J. Weinreb
Neal J. Weinreb
RKReena Kartha
Reena Kartha
Eliglustat is a glucosylceramide synthase inhibitor indicated as a long‐term substrate reduction therapy for adults with type 1 Gaucher disease, a lysosomal rare disease. It is primarily metabolized by cytochrome P450 2D6 (CYP2D6), and variants in the gene encoding this enzyme are important determinants of eliglustat pharmacokinetics (PK) and drug–drug interactions (DDIs). The existing drug label addresses the DDIs to some extent but has omitted scenarios where both metabolizing CYPs (2D6 and 3A4) are mildly or moderately inhibited. The objectives of this study were (i) to develop and validate an eliglustat physiologically‐based pharmacokinetic (PBPK) model with and without drug interactions, (ii) to simulate untested DDI scenarios, and (iii) to explore potential dosing flexibility using lower dose strength of eliglustat (commercially not available). PK data from healthy adults receiving eliglustat with or without interacting drugs were obtained from literature and used for the PBPK model development and validation. The model‐predicted single‐dose and steady‐state maximum concentration (Cmax) and area under the concentration‐time curve (AUC) of eliglustat were within 50–150% of the observed values when eliglustat was administered alone or coadministered with ketoconazole or paroxetine. Then as model‐based simulations, we illustrated eliglustat exposure as a victim of interaction when coadministered with fluvoxamine following the US Food and Drug Administration (FDA) dosing recommendations. Second, we showed that with lower eliglustat doses (21 mg, 42 mg once daily) the exposure in participants of intermediate and poor metabolizer phenotypes was within the outlined safety margin (Cmax <250 ng/mL) when eliglustat was administered with ketoconazole, where the current recommendation is a contraindication of coadministration (84 mg). The present study demonstrated that patients with CYP2D6 deficiency may benefit from lower doses of eliglustat.

8 January 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
SCShen Cheng
Shen Cheng
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
JLJ. Steven Leeder
J. Steven Leeder
Jacob T. BrownJacob T. Brown
Jacob T. Brown
Atomoxetine (ATX) is a non‐stimulant used to treat attention‐deficit/hyperactivity disorder (ADHD) and systemic exposure is highly variable due to polymorphic cytochrome P450 2D6 (CYP2D6) activity. The objective of this study was to characterize the time course of ATX and metabolites (4‐hydroxyatomoxetine (4‐OH); N ‐desmethylatomoxetine (NDA); and 2‐carboxymethylatomoxetine (2‐COOH)) exposure following oral ATX dosing in children with ADHD to support individualized dosing. A nonlinear mixed‐effect modeling approach was used to analyze ATX, 4‐OH, and NDA plasma and urine, and 2‐COOH urine profiles obtained over 24–72 hours from children with ADHD ( n = 23) following a single oral ATX dose. Demographics and CYP2D6 activity score (AS) were evaluated as covariates. Simulations were performed to explore the ATX dosing in subjects with various CYP2D6 AS. A simultaneous pharmacokinetic modeling approach was used in which a model for ATX, 4‐OH, and NDA in plasma and urine, and 2‐COOH in urine was developed. Plasma ATX, 4‐OH, and NDA were modeled using two‐compartment models with first‐order elimination. CYP2D6 AS was a significant determinant of ATX apparent oral clearance (CL/F), fraction metabolized to 4‐OH, and systemic exposure of NDA. CL/F of ATX varied almost 7‐fold across the CYP2D6 AS groups: AS 2: 20.02 L/hour; AS 1: 19.00 L/hour; AS 0.5: 7.47 L/hour; and AS 0: 3.10 L/hour. The developed model closely captures observed ATX, 4‐OH, and NDA plasma and urine, and 2‐COOH urine profiles. Application of the model shows the potential for AS‐based dosing recommendations for improved individualized dosing.

19 May 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
JRJuliane Rascher
Juliane Rascher
SCShen Cheng
Shen Cheng
CJCurtis Johnston
Curtis Johnston
SHSebastian Härtter
Sebastian Härtter
WJWojtyniak Jan‐Georg
Wojtyniak Jan‐Georg
LLLori M. B. Laffel
Lori M. B. Laffel
Aims: To characterize the pharmacokinetics (PK) and PK/pharmacodynamics (PD) regarding glycosylated haemoglobin (HbA1c) lowering using the paediatric data from DINAMO and to assess differences compared with adults.Methods: Population PK and PK/PD models previously developed for empagliflozin in adults and adolescents were re‐estimated in a Bayesian framework. The PK model included 223 observations from 74 patients receiving empagliflozin 10 mg and 25 mg and the PK/PD model used 394 observations from 103 patients receiving empagliflozin (n = 52) or placebo (n = 51).Results: Empagliflozin PK was well described by a 2‐compartment model with sequential zero‐order and first‐order absorption, with tested covariate effects of sex, age, race and estimated glomerular filtration rate on apparent clearance, and fixed allometric exponents on apparent clearance, apparent central volume of distribution, apparent intercompartmental clearance and apparent peripheral volume of distribution. Simulations of area under the curve at steady state (AUCss) demonstrated that adult and paediatric subjects exhibit similar AUCss. The PK/PD data were adequately described by a turnover model with disease progression and AUCss inhibiting the HbA1c synthesis through an inhibitory maximum effect relationship. Simulations showed that the placebo‐adjusted HbA1c decrease at Week 26 in the paediatric population was larger than that in the adult population (−0.699 vs. –0.528%).Conclusion: A Bayesian estimation framework enabled the characterization of empagliflozin PK and PK/PD with a limited number of samples in paediatric patients aged 10–17 years. Overall, the results confirm 10 and 25 mg as the appropriate empagliflozin doses in paediatric patients aged 10–17 years with type 2 diabetes mellitus.